Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database

Gabriele, Domenico; Collura, Devis; Oderda, Marco; Stura, Ilaria; Fiorito, Chiara; Porpiglia, Francesco; Terrone, Carlo; Zacchero, M.; Guiot, Caterina; Gabriele, P.

doi:10.1007/s00345-015-1669-2

Cited by 33 publications

(31 citation statements)

References 23 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for implementation of BS, several studies have suggested that the use of BS should be restricted to high-risk patients since both sensitivity and specificity of BS are relatively low and BS can only provide limited assistance to evaluate PCa in the pre-treatment stage [47,48]. Consistently, our study demonstrated that BS was less capable in sensitive detection of metastatic lesions in spine, pelvis and skull in comparison to MRI (Table 2).…”

Section: Discussionsupporting

confidence: 73%

Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels

Ning²,

Li³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The combined role of whole-body magnetic resonance imaging (WB-MRI), bone scintigraphy and prostate specific antigen (PSA) were considered in predicting metastases and prognosis of prostate cancer (PCa). Methods: Totally 38 PCa patients underwent WB-MRI, bone scintigraphy and PSA detections, and 34 benign prostate hyperplasia (BPH) patients were checked with PSA. Pearson correlations were performed to determine associations among PSA, apparent diffusion coefficient (ADC) and Gleason scoring. Specificity and sensitivity were for comparison of diagnostic accuracies. Patients' baseline PSA, PSA nadir and time to the prostate-specific antigen nadir (TTPN) were analyzed, and Kaplan-Meier survival curves were also established. Results: ADC values were negatively correlated with PSA levels (r_s = -0.389, P = 0.016) and Gleason scores (r_s = -0.432, P = 0.006), while PSA levels were positively correlated with Gleason scoring (r_s = 0.493, P = 0.002). Diagnostic efficacy of whole body-diffusion weighted imaging (WB-DWI) combined with PSA seemed the most favorable, and bone scintigraphy was advantageous in identifying bone metastasis. PSA levels (> 61.60 µg/L), Gleason scores (> 6) and ADC (< 0.81 × 10^-3 mm²/s) could all predict pessimistic prognosis (HR = 7.65; HR = 6.09; HR = 7.28). Smaller PSA nadir (≤ 1.0 µg/L) and longer TTPN (> 3 months) were associated with increased 5-year survival rate (P < 0.05). Conclusions: The combined efficacies of WB-MRI, bone scintigraphy and PSA levels were desired in identifying PCa lesions and prognosis.

show abstract

Section: Discussionsupporting

confidence: 73%

Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels

Ning²,

Li³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…found the sensitivity for CT scans of 42% and specificity of 82% . The poor performance of CT for the detection of nodal metastases has been confirmed in other recent studies …”

Section: Evidence Acquisitionmentioning

confidence: 99%

State‐of‐the‐art imaging techniques in the management of preoperative staging and re‐staging of prostate cancer

et al. 2018

View full text Add to dashboard Cite

We aimed to review the current state‐of‐the‐art imaging methods used for primary and secondary staging of prostate cancer, mainly focusing on multiparametric magnetic resonance imaging and positron‐emission tomography/computed tomography with new radiotracers. An expert panel of urologists, radiologists and nuclear medicine physicians with wide experience in prostate cancer led a PubMed/MEDLINE search for prospective, retrospective original research, systematic review, meta‐analyses and clinical guidelines for local and systemic staging of the primary tumor and recurrence disease after treatment. Despite magnetic resonance imaging having low sensitivity for microscopic extracapsular extension, it is now a mainstay of prostate cancer diagnosis and local staging, and is becoming a crucial tool in treatment planning. Cross‐sectional imaging for nodal staging, such as computed tomography and magnetic resonance imaging, is clinically useless even in high‐risk patients, but is still suggested by current clinical guidelines. Positron‐emission tomography/computed tomography with newer tracers has some advantage over conventional images, but is not cost‐effective. Bone scan and computed tomography are often useless in early biochemical relapse, when salvage treatments are potentially curative. New imaging modalities, such as prostate‐specific membrane antigen positron‐emission tomography/computed tomography and whole‐body magnetic resonance imaging, are showing promising results for early local and systemic detection. Newer imaging techniques, such as multiparametric magnetic resonance imaging, whole‐body magnetic resonance imaging and positron‐emission tomography/computed tomography with prostate‐specific membrane antigen, have the potential to fill the historical limitations of conventional imaging methods in some clinical situations of primary and secondary staging of prostate cancer.

show abstract

“…CT is often used in the initial staging of advanced disease to follow nodal involvement and bone metastasis, and is especially useful in excluding extensive osseous metastasis or evaluating pathologic fractures. Although nodal metastasis on CT is specific, there is low sensitivity [100]. …”

Section: Prostate Adenocarcinomamentioning

confidence: 99%

Advances in medical imaging for the diagnosis and management of common genitourinary cancers

Bagheri

Ahlman

Lindenberg

et al. 2017

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Medical imaging of the three most common genitourinary (GU) cancers—prostate adenocarcinoma, clear cell renal cell carcinoma (RCC), and urothelial carcinoma of the bladder—has evolved significantly during the past decades. The most commonly used imaging modalities for the diagnosis, staging, and follow-up of GU cancers are computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Multiplanar multidetector CT and multiparametric MRI (mpMRI) with diffusion-weighted imaging are the main imaging modalities for RCC and urothelial carcinoma, and while mpMRI is rapidly becoming the main imaging tool in the evaluation of prostate adenocarcinoma, biopsy is still required for diagnosis. Functional and molecular imaging using 18-fluorodeoxyglucose (FDG)-PET, and sodium fluoride (NaF)-PET are essential for the diagnosis, and especially follow-up, of metastatic GU tumors. This review will provide an overview of the latest advances in the imaging of these three major GU cancers.

show abstract

Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database

Cited by 33 publications

References 23 publications

Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels

Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels

State‐of‐the‐art imaging techniques in the management of preoperative staging and re‐staging of prostate cancer

Advances in medical imaging for the diagnosis and management of common genitourinary cancers

Contact Info

Product

Resources

About